Urinary incontinence is defined as any involuntary leakage of urine and represents a common, distressing condition that significantly impacts quality of life. It affects individuals of all ages but is particularly prevalent in women, largely due to anatomical, hormonal, and obstetric factors. Beyond the physical inconvenience, urinary incontinence can lead to social embarrassment, reduced self-confidence, sexual dysfunction, skin complications, and increased risk of institutionalisation in older adults. Understanding the underlying type of incontinence is essential, as management strategies differ according to the predominant mechanism. There are four principal types of urinary incontinence: Urgency urinary incontinence: involuntary leakage accompanied by or immediately preceded by a sudden, compelling urge to pass urine. Stress urinary incontinence: involuntary leakage occurring with physical effort, exertion, sneezing, or coughing. Mixed urinary incontinence: features of both stress and urgency incontinence. Overflow incontinence: leakage due to chronic urinary retention, typically resulting from detrusor underactivity or bladder outlet obstruction. In women, urinary incontinence is frequently associated with detrusor overactivity (particularly in urgency incontinence) or weakened pelvic floor muscles (commonly in stress incontinence). Hormonal changes, pregnancy, childbirth, and ageing contribute significantly to pelvic floor dysfunction. Adobe stock Fig 1: Stress urinary incontinence Pathophysiology Urgency incontinence is usually caused by involuntary detrusor muscle contractions during the bladder filling phase, often referred to as overactive bladder. Stress incontinence results from urethral sphincter incompetence and pelvic floor weakness, leading to inadequate resistance during rises in intra-abdominal pressure. Overflow incontinence arises when bladder emptying is incomplete, resulting in overdistension and subsequent leakage. Pharmacological Management Drug treatment is indicated when conservative measures (bladder training, pelvic floor therapy) are insufficient. Pharmacotherapy is most effective in urgency and mixed urinary incontinence, where detrusor overactivity is the primary mechanism. The main pharmacological options for urge or mixed incontinence are: 1. Antimuscarinic Agents Examples: oxybutynin, solifenacin, tolterodine, darifenacin, fesoterodine, propiverine, trospium chloride These agents work by blocking muscarinic (primarily M₃) receptors in the detrusor muscle, thereby reducing involuntary bladder contractions during the storage phase. This increases bladder capacity and reduces urgency and frequency episodes. Common adverse effects include dry mouth, constipation, blurred vision, and cognitive impairment, particularly in older adults due to anticholinergic burden. 2. β3-Adrenoceptor Agonists β₃-adrenoceptor agonists, such as mirabegron and vibegron, stimulate β₃ receptors in the detrusor muscle, promoting relaxation during the filling phase and increasing functional bladder capacity. These agents are often used as an alternative to antimuscarinics in patients who cannot tolerate anticholinergic side effects or in whom such effects are contraindicated. They are generally better tolerated but may be associated with hypertension and require blood pressure monitoring. Summary Urinary incontinence is a multifactorial and highly prevalent condition, particularly among women, with significant physical, psychological, and social consequences. Accurate identification of the type of incontinence is crucial to guide effective management. While conservative strategies remain first-line therapy, pharmacological treatment plays a central role in urgency and mixed urinary incontinence, targeting detrusor overactivity through antimuscarinic agents or β₃-adrenoceptor agonists. Rate This Article